Chlorproguanil/dapsone
(Redirected from Lapdap)
Combination of | |
---|---|
Chlorproguanil | Antimalarial drug |
Dapsone | Antibiotic |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number |
Chlorproguanil/dapsone (sold commercially as Lapdap) was a fixed dose antimalarial combination containing chlorproguanil and dapsone,[1] which act synergistically against malaria. The drug was withdrawn in 2008 following increasing evidence of toxicity in the form of haemolysis occurring in patients with G6PD deficiency.[2]
References
- ^ Lang T, Greenwood B (March 2003). "The development of Lapdap, an affordable new treatment for malaria". The Lancet. Infectious Diseases. 3 (3): 162–8. doi:10.1016/S1473-3099(03)00547-4. PMID 12614733.
- ^ Luzzatto L (August 2010). "The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics". Lancet. 376 (9742): 739–41. doi:10.1016/S0140-6736(10)60396-0. PMID 20599264. S2CID 34866078.
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs with non-standard legal status
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- Antimalarial agents
- Combination antiviral drugs
- Withdrawn drugs
- All stub articles
- Antiinfective agent stubs